請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54727
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方俊民 | |
dc.contributor.author | Bei-Tao Hong | en |
dc.contributor.author | 洪北濤 | zh_TW |
dc.date.accessioned | 2021-06-16T03:37:22Z | - |
dc.date.available | 2020-05-11 | |
dc.date.copyright | 2015-05-11 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-05-05 | |
dc.identifier.citation | 第五章:參考文獻
1. Taubenberger, J. K.; Morens, D. M. Emerg. Inf. Dis. 2006, 12, 15–22. 1918 Influenza: the mother of all pandemics. 2. Glezen, W. P. Epidemiologic Reviews 1996, 18, 64–76. Emerging infections: pandemic influenza. 3. http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html accessed on 2015/04/28 4. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/Data_Reports/en/index.html accessed on 2015/04/28 5. Kaiser, J. Science 2006, 312, 380–382. A one-size-fits-all flu vaccine? 6. Tong, S.; Zhu, X.; Li, Y.; Shi, M.; Zhang, J.; Bourgeois, M.; Yang, H.; Chen, X.; Recuenco, S.; Gomez, J.; Chen, L.-M.; Johnson, A.; Tao, Y.; Dreyfus, C.; Yu, W.; McBride, R.; Carnry, P. J.; Gilbert, A. T.; Chang, J.; Guo, Z.; Davis, C. T.; Paulson, J. C.; Wilson, I. A.; Donis, R. O. PLoS Pathog. 2013, 9, e1003657. New world bats harbor diverse influenza A viruses. 7. http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Undef&id=11308&lvl=3&lin=f&keep=1&srchmode=3&unlock accessed on 2015/04/28 8. von Itzstein, M. Nat. Rev. Drug Discovery, 2007, 6, 967–974. The war against influenza: discovery and development of sialidase inhibitors 9a. Weis, W,; Broen, J. H.; Cusack, S.; Paulson, J. C.; Skehel, J. J.; Wiley, D. C. Nature 1988, 333, 426–431. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. 9b. Skehel, J. J.; Wiley, D. C. Annu. Rev. Biochem. 2000, 69, 531–569. Receptor binding and membrane fusion in virus entry: the influenza haemagglutinin. 10a. Gamblin, S. J.; Haire, L. F.; Russell, R. J.; Stevens, D. J.; Xiao, B.; Ha, Y.; Vasisht, N.; Steinhauer, D.A.; Daniels, R. S.; Elliot, A.; Wiley, D. C.; Skehel, J. J.; Science 2004, 303, 1838–1842. The structure and receptor binding properties of the 1918 influenza haemagglutinin. 10b. Stevens, J.; Corper, A. L.; Basler, C. F.; Taubenberger, J. K.; Palese, P.; Wilson, I. A. Science 2004, 303, 1866–1870. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. 10c. Stevens, J.; Blixt, O.; Tumpey, T. M.; Taubenberger, J. K.; Paulson, J. C.; Wilson, I. A. Science 2006, 312, 404–410. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. 11. Ha, L.; Stevens, D. J.; Skehel, J. J.; Wiley, D. C. Proc. Natl. Acad. Sci. USA 2001, 98, 11181–11186. X- ray structures of H5 avian and H9 swine influenza virus hemaggultinins bound to avian and human receptor analogs 12. Rogers, G. N.; Paulson, J. C.; Daniels, R. S.; Skehel, J. J.; Wilson, I. A.; Wiley, D. C. Nature, 1988, 304, 76–78. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. 13. Moscona, A. N. Engl. J. Med. 2005, 353, 1363–1373. Neuraminidase inhibitors for influenza. 14a Varghese, J. N.; Mckimmbreschkin, J. L.; Caldwell, J. B.; Kortt, A. A.; Colman, P. M. Proteins 1992, 14, 327–332. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. 14b Colman, P. M. Protein Science 1994, 3, 1687–1696. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. 15. Bossart-Whitaker, P.; Carson, M.; Babu, Y. S.; Smith, C. D.; Laver, W. G.; Air, G. M. J. Mol. Biol. 1993, 232, 1069–1083. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic Acid. 16. Chong, A. K. J.; Pegg, M. S.; Taylor, N. R.; von Itzstein, M. Eur. J. Biochem. 1992, 207, 335–343. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus 17. Taylor, N. R.; von Itzstein, M. J. Med. Chem. 1994, 37, 616–624. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. 18. Clercq, E. D. Nature Review 2006, 5, 1015–1025. Antiviral agents active against influenza A viruses. 19. Nishimura, K.; Kim, S.; Zhang, L.; Cross, T.A. Biochemistry 2002, 41, 13170–13177. The closed state of a H+ channel helical bundle combining precise orientational and distance restraints from solid state NMR. 20. Schnell, J. R.; Chou, J. J. Nature 2008, 451, 591–595. Structure and mechanism of the M2 proton channel of influenza A virus. 21. Stouffer, A. L.; Acharya, R.; Salom, D.; Levine, A. S.; Di Costanzo, L.; Soto, C. S.; Tereshko, V.; Nanda, V.; Stayrook, S.; DeGrado, W. F. Nature 2008, 451, 596–599. Structural basis for the function and inhibition of an influenza virus proton channel. 22. Davies, W. L.; Grunert, R.R.; Haff, R. F.; McGahen, J. W.; Neumayer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hofmann, C. E. Science 1964, 144, 862–863. Antiviral activity of 1-adamantanamine (amantadine). 23. Whittaker, G. R. Exp. Rev. Mol. Med. 2001, 3, 1–13. Intracellular trafficking of influenza virus clinical implications for molecular medicine. 24. Pielak, R. M.; Schnell, J. R.; Chou, J. J. Proc. Natl. Acad. Sci. USA 2009, 106, 7379–7384. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. 25. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. JAMA. 2006, 295, 891–894. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. 26. Jones, J. C.; Turpin, E. A.; Bultmann, H.; Brandt, C. R.; Schultz-Cherry, S. J. Virol. 2006, 80, 11960–11967. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. 27. Rajik, M.; Omar, A. R.; Ideris, A.; Hassan, S. S.; Yusoff, K. Int. J. Biol. Scil. 2009, 5, 543–548. A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells. 28. Matsubara, T.; Onishi, A.; Saito, T.; Shimada, A.; Inoue, H.; Taki, T.; Nagata, K.; Okahata, Y.; Sato, T. J. Med. Chem. 2010, 53, 4441–4449. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. 29a. Bodian, D. L.; Yamasaki, R. B.; Buswell, R. L.; Stearns, J. F.; White, J. M.; Kuntz, I. D.; Biochemistry 1993, 32, 2967–2978. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. 29b. Hoffmann, L.; Kuntz, I.; White, J. J. Virol. 1997, 71, 8808–8820. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. 30a. Russell, R. J.; Kerry, P. S.; Stevens, D. J.; Steinhauer, D. A.; Martin, S. R.; Gamblin, S. J.; Skehel, J. J. Proc. Natl. Acad. Sci. USA 2008, 105, 17736–17741. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. 30b. Das, K.; Aramini, J. M.; Ma, L.-C.; Krug, R. M.; Arnold, E. Nat. Struct. Mol. Biol. 2010, 17, 530–538. Structures of influenza A proteins and insights into antiviral drug targets. 31. Plotch, S. J.; O'Hara, B.; Morin, J.; Palant, O.; LaRocque, J.; Bloom, J. D.; Lang, S. A., Jr.; DiGrandi, M. J.; Bradley, M.; Nilakantan, R.; Gluzman, Y. J. Virol. 1999, 73, 140–151. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. 32. Zhu, Z.; Li, R.; Xiao, G.; Chen, Z.; Yang, J.; Zhu, Q.; Liu, S. Eur. J. Med. Chem. 2012, 57, 211–216. Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion. 33. Yoshimoto, J.; Kakui, M.; Iwasaki, H.; Fujiwara, T.; Sugimoto, H.; Hattori, N. Arch. Virol. 1999, 144, 865–878. Identification of a novel HA conformational change inhibitor of human influenza virus. 34. Minagawa, K.; Kouzuki, S.; Kamigauchi, T. J. Antibiot. (Tokyo) 2002, 55, 165–171. Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. 35. Motohashi, Y.; Igarashi, M.; Okamatsu, M.; Noshi, T.; Sakoda, Y.; Yamamoto, N.; Ito, K.; Yoshida, R.; Kida, H. Virol. J. 2013, 20, 118–127. Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes. 36. Luo, G.; Colonno, R.; Krystal, M. Virology 1996, 226, 66–76. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. 37. Staschke, K. A.; Hatch, S. D.; Tang, J. C.; Hornback, W. J.; Munroe, J. E.; Colacino, J. M.; Muesing, M. A. Virology 1998, 248, 264–274. Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. 38. Tang, G.; Lin, X.; Qiu, Z.; Li, W.; Zhu, L.; Wang, L.; Li, S.; Li, H.; Lin, W.; Yang, M.; Guo, T.; Chen, L.; Lee, D.; Wu, J. Z. Yang, W. ACS. Med. Chem. Lett. 2011, 2, 603–607. Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors. 39. Meindl, P.; Bodo, G.; Palese, P.; Schulman, J.; Tuppy, H. Virology 1974, 58, 457–463. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. 40. Von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Nature 1993, 363, 418–423. Rational design of potent sialidase-based inhibitors of influenza virus replication. 41. Holzer, C. T.; von Itzstein, M.; Jin, B.; Pegg, M. S.; Stewart, W. P.; Wu, W.-Y. Glycoconj. J. 1993, 10, 40–44. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. 42. Woods, J. M.; Bethell, R. C.; Coates, J. A.; Healy, N.; Hiscox, S. A.; Pearson, B. A.; Ryan, D. M.; Ticehurst, J.; Tilling, J.; Walcott, S. M. Antimicrob. Agents Chemother. 1993, 37, 1473–1479. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. 43. Ryan, D. M.; Ticehurst, J.; Dempsey, M. H.; Penn, C. R. Antimicrob. Agents Chemother. 1994, 38, 2270–2275. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). 44a. Dunn, C. J.; Goa, K. L. Drugs 1999, 58, 761–784. Zanamivir: a review of its use in influenza. 44b. Elliott, M. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1885–1893. Zanamivir: from drug design to the clinic. 45. Andrews, D. M.; Cherry, P. C.; Humber, D. C.; Jones, P. S.; Keeling, S. P.; Martin, P. F.; Shaw, C. D.; Swanson, S. Eur. J. Med. Chem. 1999, 34, 563–574. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain. 46. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kobayashi, Y.; Yamashita, M. Bioorg. Med. Chem. Lett. 2002, 12, 1921–1924. Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. 47. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Bioorg. Med. Chem. Lett. 2002, 12, 1925–1928. Synthesis and anti-Influenza virus activity of 7-O-Alkylated derivatives related to zanamivir. 48. Honda, T.; Kubo, S.; Masuda, T.; Arai, M.; Kobayashi, Y.; Yamashita, M. Bioorg. Med. Chem. Lett. 2009, 19, 2938–2940. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. 49. Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H. Kubo, S. Antimicrob. Agents Chemother. 2009, 53, 186–192. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. 50. Kubo, S.; Tomozawa, T.; Kakuka, M.; Tokumitsu, A.; Yamashita, M. Antimicrob. Agents Chemother. 2010, 54, 1256–1264. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. 51. Ishizuka, H.; Yoshiba, S.; Okabe, H.; Yoshiahara, K. J. Clin. Pharmacol. 2010, 50, 1319–1329. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. 52. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. J. Am. Chem. Soc. 1997, 119, 681–690. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. 53. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. J. Med. Chem. 1998, 41, 2451–2460. Structure−activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. 54a. Mendel, D. B.; Tai, C. Y.; Escarpe, P. A.; Li, W.; Sidwell, R. W.; Huffman, J. H.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lacy, S. A.; Lew, W.; Williams, M. A.; Zhang, L.; Chen, M. S.; Bischofberger, N.; Kim, C. U. Antimicrob. Agents Chemother. 1998, 42, 640–646. Oral Administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. 54b. Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. B. Antimicrob. Agents Chemother. 1998, 42, 647–653. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. 54c. Sidwell, R. W.; Huffman, J. H.; Barnard, D. L.; Bailey, K. W.; Wong, M. H.; Morrison, A.; Syndergaard, T.; Kim, C. U. Antiviral Res. 1998, 37, 107–120. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. 55. Yamamoto, T.; Kumazawa, H.; Inami, K.; Teshima, T.; Shiba, T. Tetrahedron Lett. 1992, 33, 5791–5794. Syntheses of sialic acid isomers with inhibitory activity against neruaminidase. 56. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T.-H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. J. Med. Chem. 2000, 43, 3482–3486. BCX-1812 (RWJ-270201): Discovery of novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. 57. Young, D.; Fowler, C.; Bush, K. Phil. Trans. R. Soc. Lond. B 2001, 356, 1905–1913. RWJ-270201 (BCX-1812): A novel neuraminidase inhibitor for influenza. 58. Belshe, R. B. N. Engl. J. Med. 2005, 353, 2209–2211. The origins of pandemic influenza - lessons from the 1918 virus. 59. McKimm-Breschkin, J. L. Antiviral Res. 2000, 47, 1–17. Resistance of influenza viruses to neuraminidase inhibitors - a review. 60a. de Jong, M. D.; Thanh, T. T.; Khanh, T. H.; Hien, V. M.; Smith, G. J. D.; Chau. N. V.; Cam, B. V.; Qui, P. T.; Ha, D. Q.; Guan, Y.; Peiris, J. S. M.; Phil, D.; Hien, T. T.; Farrar, J. N. Engl. J. Med. 2005, 353, 2667–2672. Brief report: Oseltamivir resistance during treatment of influenza A (H5N1) Infection. 60b. Le, Q. M.; Kiso, M.; Someya, K.; Sakai, Y. T.; Nguyen, T. H.; Nguyen, K. H. L.; Pham, N. D.; Ngyen, H. H.; Yamada, S.; Muramoto, Y.; Horimoto, T.; Takada, A.; Goto, H.; Suzuki, T.; Suzuki, Y.; Kawaoka, Y. Nature 2005, 437, 1108. Avain flu: isolation of drug-resistant H5N1 virus. 61. Dharan, N. J.; Gubareva, L. V.; Meyer, J. J.; Okomo-Adhiambo, M.; McClinton, R. C.; Marshall, S. A.; St. George, K.; Epperson, S.; Brammer, L.; Klimov, A. I.; Bresee, J. S.; Fry, A. M. JAMA 2009, 301, 1034–1041. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. 62. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J. F.; Russell, R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Nature 2008, 453, 1258–1261. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. 63. Shie, J.-J.; Fang, J.-M.; Wang, S.-Y.; Tasi, K.-C.; Cheng, Y.-S. E.; Yang, A.-S.; Hsiao, S.-C.; Su, C.-Y.; Wong, C.-H. J. Am. Soc. Chem. 2007, 129, 11892–11893. Synthesis of Tamiflu and its phosphonate congeners possessing potent anti- influenza activity. 64. Cheng, T.-J. R.; Weinheimer, S.; Tarbet, E. B.; Jan, J.-T.; Cheng, Y.-S. E.; Shie, J.-J.; Chen, C.-L.; Chen, C.-A.; Hsieh, W.-C.; Huang, P.-W.; Lin, W.-H.; Wang, S-Y.; Fang, J.-M.; Hu, O. Y.-P.; Wong, C.-H. J. Med. Chem. 2012, 55, 8657–8670. Development of oseltamivir congeners as anti-influenza agents. 65. Langmuir, I. J. Am. Soc. Chem. 1919, 41, 1543–1559. Isomorphism, isoteriam and covalence. 66. von Hans, E.; Martin, L. Helv. Chim. Acta. 1932, 15, 1171–1186. Über pseudoatome. 67. Friedman H. L. Washington D.C. Natl Acad. Sci. 1951, 206. 295. Influence of isosteric replacements upon biological activity. 68. Thornber, C. W. Chem. Soc. Rev. 1979, 8, 563–580. Isosterism and molecular modification in drug design. 69. Burger A. Prog. Drug Res. 1991, 37, 287–371. Isosterism and bioisosterism in drug design. 70. Patani, G. A.; LaVoie, E. J. Chem. Rev. 1996, 96, 3147–3176. Bioisosterism: a rational approach in drug design. 71. Ballatore, C.; Huryn, D. M.; Smith, A. B., III ChemMedChem 2013, 8, 385–395. Carboxylic acid (bio)isosteres in drug design. 72. Venture, O. N.; Rama, J. B.; Turi, L.; Dannenberg, J. J. J. Am. Chem. Soc. 1993, 115, 5754–5761. Acidity of hydroxamic acids : an ab initio and semiempirical study 73a. Bauer, L.; Exner, O. Angew. Chem. Int. Ed. Engl. 1974, 13, 376–384. The chemistry of hydroxamic acids and N-hydroxyimides. 73b. Böhm, S.; Exner, O. Org. Biomol. Chem. 2003, 1, 1176–1180. Acidity of hydroxamic acids and amides. 74. Sanderson, L.; Taylor, G. W.; Aboagye, E. O.; Alao, J. P.; Latigo, J. R.; Coombes, R. C.; Vigushin, D. M. Drug Metab. Dispos. 2004, 32, 1132–1138. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. 75. Barrett, S. D.; Bridges, A. J.; Dudley, D. T.; Saltiel, A. R.; Fergus, J. H.; Flamme, C. M.; Delaney, A. M.; Kaufman, M.; LePage, S.; Leopold, W. R.; Przybranowski, S. A.; Sebolt-Leopold, J.; Van Becelaere, K.; Doherty, A. M.; Kennedy, R. M.; Marston, D.; Howard, W. A. Jr.; Smith, Y.; Warmus, J. S.; Tecle, H. Bioorg. Med. Chem. Lett. 2008, 18, 6501–6504. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. 76. Franz, R. G. AAPS PharmSci 2001, 3, 1–13. Comparisons of pKa and logP values of some carboxylic and phosphonic acids: synthesis and measurement. 77a. Kerr, D. I. B.; Ong, J.; Prager, R. H.; Gynther, B. D.; Curtis, D. R. Brain Res. 1987, 405, 150–154. Phaclofen: a peripheral and central baclofen antagonist. 77b. Froestl, W.; Mickel, S. J.; Hall, R. G.; von Sprecher, G.; Strub, D.; Baumann, P. A.; Brugger, F.; Gentsch, C.; Jaekel, J.; J. Med. Chem. 1995, 38, 3297–3312. Phosphinic acid analogues of GABA. 1. new potent and selective GABAB agonists. 78. Drysdale, M. J.; Pritchard, M. C.; Horwell, D. C. J. Med. Chem. 1992, 35, 2573–2581. Rationally designed “dipeptoid” analogues of CCK. acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. 79a. Woods, D. D. Br. J. Exp. Pathol. 1940, 21, 74–90. The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide. 79b. Bell, P. H.; Roblin, R. O.; J. Am. Chem. Soc. 1942, 64, 2905–2917. Studies in chemotherapy. VII. a theory of the relation of structure to activity of sulfanilamide type compounds. 80. King J. F. in The Chemistry of Sulphonic Acids, Esters and their Derivatives, Wiley, Chichester, 1991, pp. 249–259. 81. Yee, Y. K.; Bernstein, P. R.; Adams, E. J.; Brown, F. J.; Cronk, L. A.; Hebbel, K. C.; Vacek, E. P.; Krell, R. D.; Snyder, D. W. J. Med. Chem. 1990, 33, 2437–2451. A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. 82. Ducharme, Y.; Blouin, M.; Carriere, M. C.; Chateauneuf, A.; Cote, B.; Denis, D.; Frenette, R.; Greig, G.; Kargman, S.; Lamontagne, S.; Martins, E.; Nantel, F.; O’Neill, G.; Sawyer, N.; Metters, K. M.; Friesen, R. W. Bioorg. Med. Chem. Lett. 2005, 15, 1155–1160. 2,3-Diarylthiophenes as selective EP1 receptor antagonists. 83. Miyaura N.; Suzuki A. Chem. Rev. 1995, 95, 2457–2483. Palladium-catalyzed cross-coupling reactions of organoboron compounds. 84. Dembitsky, V. M.; Smoum, R.; Al-Quntar, A. A.; Ali, H. A.; Pergament, I.; Srebnik, M. Plant Sci. 2002 , 163, 931–942. Natural occurrence of boron-containing compounds in plants, algae and microorganisms. 85. Chen, X.; Schauder, S.; Potier, N.; Van Dorsselaer, A.; Pelczer, I.; Bassler, B. L.; FHughson, F. M. Nature 2002, 415, 545–549. Structural identification of a bacterial quorum-sensing signal containing boron. 86. Adams, J.; Kauffman, M. Cancer Invest. 2004, 22, 304–311. Development of the proteosome inhibitor Velcade (Bortezomib). 87a. Lennarz, W. J.; Snyder, H. R. J. Am. Chem. Soc. 1960, 82, 2172. Arylboronic acids. IV. reactions of boronophthalide. 87b. Haynes, R. R.; Snyder, H. R. J. Org. Chem. 1964, 29, 3229. Arylboronic acids. VIII. reactions of boronophthalide. 88. Baker, S. J.; Zhang, Y. K.; Akama, T,; Lau, A.; Zhou, H.; Hernandez, V.; Mao, W.; Alley, M. R. K.; Sanders, V.; Plattner, J. J. J. Med. Chem. 2006, 49, 4447–4450. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1- hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. 89. Vedejs, E.; Chapman, R. W.; Fields, C.; Lin, S.; Schrimpf, M. R. J. Org. Chem. 1995, 60, 3020–3027. Conversion of arylboronic acids into potassium aryltrifluoroborates: convenient precursors of arylboron difluoride Lewis acids. 90. Darses, S.; Genet, J.–P. Chem. Rev. 2008, 108, 288–325. Potassium organotrifluoroborates: new perspectives in organic synthesis. 91. Smoum, R.; Rubinstein, A.; Srebnik, M. Org. Biomol. Chem. 2005, 3, 941–944. Noncovalent inhibition of the serine proteases, α-chymotrypsin and trypsin by trifluoro(organo)borates. 92. Lecat-Guillet, N.; Ambroise, Y. ChemMedChem 2008, 3, 1207–1209. Discovery of aryltrifluoroborates as potent sodium/iodide symporter (NIS). 93. Brook, M. A. Silicon in Organic, Organometallic, and Polymer Chemistry; John Wiley & Sons: New York, 2000. 94. Rennison, B. D. J. Hyg., Camb. 1974, 73, 45–48. Field trials of the rodenticide 5-p -chlorophenyl silatrane against wild rats (Rattus norvegicus Berk.) 95. de Medina, P.; Boubekeur, N.; Balaguer, P.; Favre, G.; Silvente-Poirot, S.; Poirot, M. J. Pharmacol. Exp. Ther. 2006, 319, 139–149. The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1- phenylethyl]propanamide], is an agonist of estrogen receptors. 96. Chen, C. A.; Sieburth, S. M.; Glekas, A.; Hewitt, G. W.; Trainor, G. L.; Erickson-Viitanen, S.; Garber, S. S.; Cordova, B.; Jeffry, S.; Klabe, R. M. Chem. Biol. 2001, 8, 1161–1166. Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. 97. Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Warneck, J. B. H.; Tacke, R. Organometallics 2006, 25, 1188–1198. Sila-venlafaxine, a sila-analogue of the serotonin/noradrenaline reuptake inhibitor venlafaxine: synthesis, crystal structure analysis, and pharmacological characterization. 98. Wang, J.; Ma, C.; Wu, Y.; Lamb, R. A.; Pinto, L. H.; DeGrado, W. F. J. Am. Chem. Soc. 2011, 133, 13844–13847. Exploring organosilane amines as potent inhibitors and structural probes of influenza A virus M2 proton channel. 99. 陳俊霖,發展零流感單磷酯衍生物作為有效的抗流感試劑:合成與藥物動力之研究;台灣大學化學系博士論文,2013. 100. Shie, J.-J.; Fang, J.-M.; Wong, C.-H. Angew. Chem. Int. Ed. 2008, 47, 5788–5791. A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor. 101. Chen, C.-L.; Lin, T.-C.; Wang, S.-Y.; Shie, J.-J.; Tsai, K.-C.; Cheng, Y.-S. E.; Jan, J.-T.; Lin, C.-J.; Fang, J.-M.; Wong, C.-H. Eur. J. Med. Chem. 2014, 81, 106–118. Tamiphosphor monoesters as effective anti-influenza agents. 102. Fujinaga, M.; Suetake, K.; Gyoji, K.; Murafuji, T.; Kurotobi, K.; Sugihara, Y. Synthesis 2008, 23, 3745–3748. An easy access to 2-substituted azulenes from azulene-2-boronic acid pinacol ester. 103. Yuen, A. K. L.; Hutton, C. A. Tetrahedron Lett. 2005, 46, 7899–7903. Deprotection of pinacolyl boronate esters via hydrolysis of intermediate potassium trifluoroborates 104. Molander, G. A.; Cavalcanti, L. N.; Canturk, B.; Pan, P.-S.; Kennedy, L. E. J. Org. Chem. 2009, 74, 7364–7369. Efficient hydrolysis of organotrifluoroborates via silica gel and water. 105. Kabalka, G. W.; Coltuclu, V. Tetrahedron Lett. 2009, 50, 6271–6272. Thermal and microwave hydrolysis of organotrifluoroborates mediated by alumina. 106. Niestroj, M.; Lube, A.; Neumannt, W. P. Chem. Ber. 1995, 128, 575–580. Synthesis of aromatic and olefinic sodium sulfonates by electrophilic destannylation with trimethylsilyl chlorosulfonate. 107. Murata, M.; Watanabe, S.; Masuda, Y. Synlett. 2000, 7, 1043–1045. Palladium-catalyzed cross-coupling reaction of tributyltin hydride with aryl iodides: formation of a tin-carbon bond. 108. Jiang, Y.; Qin, Y.; Xie, S.; Zhang, X.; Dong, J.; Ma, D. Org. Lett. 2009, 11, 5250–5253. A general and efficient approach to aryl thiols: CuI-catalyzed coupling of aryl iodides with sulfur and subsequent reduction. 109. Kreis, M.; Bräse, S. Adv. Synth. Catal. 2005, 47, 313–319. A general and efficient method for the synthesis of silyl-protected arenethiols from aryl halides or triflates. 110. Katritzky, A. R.; Khan, G. R.; Schwarz, O. A. Tetrahedron Lett. 1984, 25, 1223–1226. Pyridylethylation - a new protection method for active hydrogen compounds. 111. Itoh, T.; Mase, T. Org. Lett. 2004, 6, 4587–4590. A general palladium-catalyzed coupling of aryl bromides/triflates and thiols. 112. Iwamoto, T., Hiraku, Y., Oikawa, S., Mizutani, H., Kojima, M., Kawanishi, S. Cancer Sci. 2004, 95, 454–458. DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. 113. Dong, X., Sang, R., Wang, Q., Tang, X.-Y., Shi, M. Chem. Eur. J. 2013, 19, 16910–16915. Copper-catalyzed trifluoromethylation and cyclization of aromatic- sulfonyl-group-tethered alkenes for the construction of 1,2-benzothiazinane dioxide type compounds. 114. Larpent, C., Patin H., Thilmont, N., Valdor, J. F. Synth. Commun. 1991, 21, 495–503. A new route to water-soluble sulfonated phosphines. 115. Sikkema, F. D., Comellas-Aragonès, M., Fokkink, R. G., Verduin, B. J. M.. M. Cornelissen, J. J. L. M., Nolte, R. J. M. Org. Biomol. Chem. 2007, 5, 54–57.Monodisperse polymer–virus hybrid nanoparticles. 116. Czifrák, K.; Somsák, L. Carbohydr. Res. 2009, 344, 269– 277. Synthesis of anomeric sulfonamides and their behavior under radical-mediated bromination conditions. 117. Chan, W. Y.; Berthelette, C. Tetrahedron Lett. 2002, 43, 4537–4540. A mild, efficient method for the synthesis of aromatic and aliphatic sulfonamides. 118. Caddick, S.. Wilden, J. D., Judd, D. B. J. Am. Chem. Soc. 2004,126, 1024–1025. Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids. 119. Chantarasriwong, O., Jang, D. O., Chavasiri, W. Tetrahedron Lett. 2006, 47, 7489–7492. A practical and efficient method for the preparation of sulfonamides utilizing Cl3CCN/PPh3. 120. Luca, L. D., Giacomelli, G. J. Org. Chem. 2008, 73, 3967–3969. An easy microwave-assisted synthesis of sulfonamides directly from sulfonic acids. 121. Rad, M. N. S., Khalafi-Nezhad, A., Asrari, Z., Behrouz, S., Amini, Z., Behrouz, M. Synthesis 2009, 23, 3983–3988. One-pot synthesis of sulfonamides from primary and secondary amine derived sulfonate salts using cyanuric chloride. 122. Blotny, G. Tetrahedron Lett. 2003, 44, 1499–1501. A new, mild preparation of sulfonyl chlorides. 123. Gooßen, L. J.; Ferwanah, A.-R. S. Synlett. 2000, 12, 1801–1803. A mild and efficient protocol for the catalytic silylation of aryl bromides. 124. Murata, M.; Watanabe, S.; Masuda, Y. Tetrahedron Lett. 1999, 40, 9255–9257. Synthesis of alkenylsilanes via palladium(0)-catalyzed silylation of alkenyl iodides with hydrosilane. 125. Iizuka, M.; Kondo, Y. Eur. J. Org. Chem. 2008, 7, 1161–1163. Palladium-catalyzed silylation of electron-deficient aryl iodides using triorganosilane in the presence of pyridine and LiCl. 126. Hamze, A.; Provot, O.; Alami, M.; Brion, J.-D. Org. Lett. 2006, 8, 931–934. Platinum oxide catalyzed silylation of aryl halides with triethylsilane: an efficient synthetic route to functionalized aryltriethylsilanes. 127. Yamanoi, Y. J. Org. Chem. 2005, 70, 9607–9609. Palladium-catalyzed silylations of hydrosilanes with aryl halides using bulky alkyl phosphine. 128. Shirakawa, E.; Kurahashi, T.; Yoshida, H.; Hiyama, T. Chem. Commun. 2000, 1895–1896. Diphenylphosphinophenolate: a ligand for the palladium-catalysed silylation of aryl halides activating simultaneously both palladium and silicon. 129. Wiedemann, M.; Heiner, T.; Mloston, G.; Prakash, G. K. S.; Olah, G. A. Angew. Chem. Int. Ed. 1998, 37, 820–821. Direct preparation of trifluoromethyl ketones from carboxylic esters: trifluoromethylation with (trifluoromethyl)trimethylsilane. 130. Singh, R. P.; Cao, G.; Kirchmeier, R. L.; Shreeve, J. M. J. Org. Chem. 1999, 64, 2873–2876. Cesium fluoride catalyzed trifluoromethylation of esters, aldehydes, and ketones with (trifluoromethyl)trimethylsilane. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54727 | - |
dc.description.abstract | 流行性感冒在近百年來是個常見且對人類健康有著重大威脅的疾病;目前抗流感病毒的藥物主要有兩種:針對M2 離子通道以及神經胺酸酶(NA);然而,因為有嚴重副作用以及病毒抗藥性的緣故,amantadine與rimantadine 這兩種針對M2 離子通道的藥物已經很少被用來治療流感;相較之下,被設計用來防止病毒離開宿主細胞醣蛋白的NA抑制劑,則是廣泛地運用在治療流感。
身為前驅藥物,且會被水解酶轉換成有作用力的酸基的克流感oseltamivir phosphate,則被用來作為第一線的治療選擇;oseltamivir carboxylic acid (OC)的酸基會與流感病毒的NA的S1部位上三個arginine的鹼基(Arg118, Arg292 and Arg371)之間有很強的靜電吸引力;不過流感病毒的突變相當迅速,最常見的抗藥性突變株病毒是最先在2007年於挪威被發現的H275Y病毒株,並在數年間就造成全球性地傳播;因此,開發嶄新的抗流感藥物是目前相當緊急的課題。 在過去幾年,本實驗室已開發出oseltamivir的磷酸等配體及其胍基衍生物;在本次研究中,我們則是利用醯胺鍵形成反應合成oseltamivir的醯基羥胺、醯基磺胺等配體與它們的胍基衍生物。在醯基羥胺衍生物中,我們發現增加此類衍生物官能基的疏水性時,會增加其抑制能力 (化合物25);但同時我們也觀察到另一不尋常的趨勢,醯基羥胺的胍基化合物29與33的抑制能力竟然比胺基化合物差,但是此二者對於突變株的抑制活性卻比OC還要來的好;與此相比,胍基化合物28反而這一系列中對野生型最有效,但對於突變株的抑制活性卻是遠不如另外兩個化合物。在醯基磺胺衍生物中,雖然觀察到具有長碳鏈以及苯環的化合物抑制能力相近,但卻比不上僅有甲基衍生的化合物35與40。 在另一方面,我們也利用了過渡金屬耦合反應合成oseltamivir與它們的胍基衍生物;在這些衍生物中,化合物64, 66, 71, 73, 86及87的抑制能力與OC不相上下,甚至還略高些許。 因此本研究可以提供相當多的資訊,有助於流感藥物之開發。 | zh_TW |
dc.description.abstract | Influenza is a common disease and has been a threat to human health over centuries. There are two classes of anti-influenza drugs approved to target the virus M2 ion channel and neuraminidase (NA), respectively. Nevertheless, the M2 ion channel inhibitors amantadine and rimantadine are no longer recommended for treatment of influenza infection due to their severe side effects and drug resistance. Neuraminidase inhibitors, designed to prevent the cleavage of terminal sialic acid residue on the surface glycoprotein of host cells, are effectively used for the treatment of influenza infection.
Oseltamivir, which is a prodrug and will be converted to the active acid by esterases, is taken as the front-line therapeutic option. The carboxylate group of oseltamivir carboxylic acid (OC) provides strong electrostatic interactions with the three arginine residues (Arg118, Arg292 and Arg371) in the S1 site of influenza NA. However, the drug-resistant influenza viruses have emerged. The most common and clinically relevant oseltamivir-resistant influenza virus is the H275Y strain, which was firstly found in Norway in 2007 and spread globally in a few years. Therefore, the development of novel anti-influenza agents is urgently needed. In the past years, our research team has developed some phosphonate congeners of oseltamivir and guanidino-oseltamivir. In this study, we synthesized the oseltamivir hydroxamates, acyl sulfonamides, and their guanidino derivatives via amide bond formation. We find that the inhibition abilities increase when the functional group of amino hydroxamate derivatives was replaced by more hydrophobic groups (compound 25). We also observed that guanidino hydroxamate compound 29 and 33 show better EC50 than OC against mutant H275Y influenza virus, though these two compounds have poorer inhibition efficiency than amino ones in the WSN assays. Interestingly, the guanidino hydroxamate compound 28 has the best EC50 in WSN assay with the poorest effect among the guanidino hydroxamate derivatives in H275Y assay. On the other hand, the n-butyl and phenyl acyl sulfonamides have similar inhibition abilities, but the methyl derivatives 35 and 40 achieve the best potency among the acyl sulfonamide derivatives. We also synthesized OC and GOC derivatives by transition-metal catalyzed coupling reactions. Some of these derivatives (64, 66, 71, 73, 86 and 87) demonstrate the inhibition efficiency similar to OC, or even better. In summry, this study provides useful information for development of novel anti-influenza drugs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:37:22Z (GMT). No. of bitstreams: 1 ntu-104-D97223111-1.pdf: 12083134 bytes, checksum: c69f3170125a5f4da6e541acef237040 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 目錄 ………………………………………………………………………………… I
圖目錄 …………………………………………………………………………… V 表目錄 …………………………………………………………………………… VII 流程目錄 ……………………………………………………………………… X 簡稱用語對照表 ………………………………………………………… XII 英文摘要 ……………………………………………………………………… XIV 中文摘要 ……………………………………………………………………… XVI | |
dc.language.iso | zh-TW | |
dc.title | 設計與合成嶄新克流感生物等配體作為有效抗流感試劑 | zh_TW |
dc.title | Design and Synthesis of Novel Oseltamivir Bioisosteres as Effective Anti-Influenza Agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 羅禮強,王宗興,梁碧惠,林俊宏,陳榮傑 | |
dc.subject.keyword | 流感,克流感,生物等配體, | zh_TW |
dc.subject.keyword | influenza,oseltamivir,bioisostere, | en |
dc.relation.page | 224 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-05-06 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 11.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。